Thomas Patrick Kelly
CIK 1410514 · Chief Financial Officer · last filed 2026-10-16
Thomas Patrick Kelly is a Chief Financial Officer who has filed 38 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for XENE, was dated Oct 16, 2026. Across all open-market trades the lifetime net is −$6.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $819.7K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DCPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
200 SMITH STREET
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XENE | Chief Financial Officer | 22,500 | $36.43 | $819.7K | $559.7K | 3 | 2026-10-16 |
| Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Chief Financial Officer | 0 | $25.59 | $0 | -$6.54M | 31 | 2024-06-11 |
| CORNERSTONE THERAPEUTICS INC (CRTX) Delisted | CFO & SVP Finance & Corp. Dev, | 90,700 | $1.95 | $176.9K | $8.3K | 4 | 2008-02-19 |
Recent Filings
38 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-16 | XENE | Exer (M) | +7,500 | $0 | EDGAR |
| 2026-10-01 | XENE | Buy (P) | +15,000 | $559.7K | EDGAR |
| 2025-10-17 | XENE | Grant (A) | — | $0 | EDGAR |
| 2024-06-11 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Mixed | −80,350 | $0 | EDGAR |
| 2024-02-20 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Mixed | +14,265 | -$47.0K | EDGAR |
| 2024-01-18 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Sell (S) | −2,435 | -$35.2K | EDGAR |
| 2023-12-14 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Mixed | +5,452 | -$42.9K | EDGAR |
| 2023-10-31 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Mixed | +5,928 | -$27.8K | EDGAR |
| 2023-06-21 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Sell (S) | −1,655 | -$23.8K | EDGAR |
| 2023-02-17 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Mixed | +15,118 | -$20.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.